---
title: "Transient Ischemic Attack (TIA)"
description: "Clinical decision support for TIA evaluation, risk stratification, and secondary prevention"
version: "1.0"
setting: "ED, HOSP, OPD"
status: approved
tags:
  - cerebrovascular
  - stroke
  - TIA
  - outpatient
  - emergency
---

# Transient Ischemic Attack (TIA)

**DIAGNOSIS:** Transient Ischemic Attack
**ICD-10:** G45.9 (Transient cerebral ischemic attack, unspecified)
**SYNONYMS:** Transient ischemic attack, TIA, mini-stroke, transient cerebral ischemia, cerebral TIA, transient neurological deficit, warning stroke, pre-stroke
**SCOPE:** Urgent evaluation, risk stratification (ABCD2), and secondary stroke prevention. Excludes completed stroke (see Acute Ischemic Stroke protocol).

**STATUS:** Approved

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| CBC with differential | Polycythemia, thrombocytosis as stroke risk; anemia evaluation | Normal | STAT | STAT | ROUTINE | - |
| BMP | Electrolytes; glucose for hypoglycemia mimic; creatinine for contrast | Normal | STAT | STAT | ROUTINE | - |
| Glucose (fingerstick) | Rule out hypoglycemia as TIA mimic | 70-180 mg/dL | STAT | STAT | - | - |
| PT/INR, PTT | Baseline coagulation; evaluate if on anticoagulation | Normal or therapeutic | STAT | STAT | ROUTINE | - |
| Lipid panel (fasting) | LDL target <70 for secondary prevention | LDL <70 mg/dL | - | ROUTINE | ROUTINE | - |
| HbA1c | Diabetes assessment; target <7% | <7% | URGENT | ROUTINE | ROUTINE | - |
| TSH | Hyperthyroidism associated with atrial fibrillation | Normal | - | ROUTINE | ROUTINE | - |
| Troponin | Concurrent cardiac ischemia; AF with rapid rate | Negative | STAT | STAT | - | - |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Homocysteine | Elevated levels increase stroke risk | <15 μmol/L | - | ROUTINE | ROUTINE | - |
| Lipoprotein(a) | Independent cardiovascular risk marker | <30 mg/dL | - | ROUTINE | ROUTINE | - |
| hsCRP | Inflammatory marker; guides statin intensity | <2 mg/L | - | ROUTINE | ROUTINE | - |
| BNP/NT-proBNP | Heart failure; cardiac strain; AF risk | Age-adjusted normal | URGENT | ROUTINE | ROUTINE | - |
| Uric acid | Elevated associated with increased stroke risk | <6 mg/dL | - | ROUTINE | ROUTINE | - |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Hypercoagulability panel | Age <50, cryptogenic, recurrent events; includes Factor V Leiden, prothrombin mutation, protein C/S, antithrombin III | Negative | - | EXT | EXT | - |
| Antiphospholipid antibodies | Lupus anticoagulant, anticardiolipin, anti-β2GP1; young stroke | Negative | - | EXT | EXT | - |
| Hemoglobin electrophoresis | Sickle cell disease if not known | No sickling | - | EXT | EXT | - |
| ESR, ANA | Suspected vasculitis | Normal/Negative | - | EXT | EXT | - |
| Fabry disease testing (α-galactosidase A) | Young cryptogenic stroke, family history, angiokeratomas | Normal enzyme activity | - | - | EXT | - |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| CT Head non-contrast | Immediate | No hemorrhage; rule out stroke mimic | None | STAT | STAT | - | - |
| MRI Brain with DWI | Within 24 hours | No restricted diffusion (DWI+/ADC-) confirming infarct vs true TIA | MRI-incompatible devices | URGENT | STAT | - | - |
| CTA Head and Neck | Same visit | No significant stenosis (>50%) in carotid, vertebral, or intracranial vessels | Contrast allergy, CKD (relative) | STAT | STAT | - | - |
| MRA Head and Neck | Alternative to CTA | Patent vessels; no stenosis >50% | MRI contraindications | URGENT | STAT | ROUTINE | - |
| Carotid duplex ultrasound | Within 24-48 hours | <50% stenosis bilaterally | None | URGENT | STAT | ROUTINE | - |
| ECG (12-lead) | Immediate | Sinus rhythm; no AF, LVH, or acute changes | None | STAT | STAT | ROUTINE | - |
| Transthoracic echocardiogram | Within 24-48 hours | No thrombus, PFO, or significant valvular disease | None | URGENT | STAT | ROUTINE | - |

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| Cardiac telemetry (continuous) | 24-72 hours minimum | No atrial fibrillation or flutter | None | URGENT | STAT | - | - |
| Holter monitor (24-48 hour) | Outpatient | No paroxysmal AF | None | - | - | ROUTINE | - |
| Extended cardiac monitoring (14-30 day) | Cryptogenic stroke/TIA | Detect paroxysmal AF | None | - | - | ROUTINE | - |
| Transesophageal echocardiogram | Cryptogenic, young, embolic | No PFO, LAA thrombus, aortic arch atheroma | Esophageal pathology | - | URGENT | EXT | - |
| Bubble study (TTE or TEE) | Suspected paradoxical embolism | No right-to-left shunt | None specific | - | URGENT | ROUTINE | - |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| CT/MR perfusion | Uncertain timing, large vessel occlusion symptoms | No mismatch suggesting salvageable tissue | Contrast issues | EXT | EXT | - | - |
| Vessel wall MRI | Suspected intracranial vasculitis or dissection | No vessel wall enhancement | MRI contraindications | - | EXT | EXT | - |
| DSA (cerebral angiogram) | Vasculitis workup, moyamoya, uncertain vessel status | Define vascular anatomy | Contrast allergy, bleeding risk | - | EXT | EXT | - |
| Implantable loop recorder | Recurrent cryptogenic events after negative workup | Detect occult AF | None | - | - | EXT | - |

---

## 3. TREATMENT

### 3A. Acute/Emergent

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Aspirin | PO | Immediate antiplatelet therapy | 325 mg PO x1 load; 81 mg PO daily :: PO :: :: 325 mg loading dose, then 81 mg daily ongoing | Active GI bleed; aspirin allergy; planned thrombolysis | GI symptoms, bleeding | STAT | STAT | ROUTINE | - |
| Clopidogrel (DAPT with aspirin) | PO | ABCD2 ≥4 or minor stroke; first 21 days | 300 mg PO x1 load; 75 mg PO daily :: PO :: :: 300 mg load then 75 mg daily with aspirin x21 days (POINT/CHANCE protocol) | Active bleeding; planned surgery within 7 days | Bleeding, bruising | STAT | STAT | ROUTINE | - |
| Ticagrelor (alternative DAPT) | PO | Aspirin + ticagrelor if clopidogrel contraindicated | 180 mg PO x1 load; 90 mg PO BID :: PO :: :: 180 mg load then 90 mg BID with aspirin x30 days (THALES protocol) | Active bleeding; prior ICH; severe hepatic impairment | Bleeding, dyspnea | STAT | STAT | ROUTINE | - |
| Atorvastatin | PO | High-intensity statin for LDL <70 | 80 mg PO daily :: PO :: :: 80 mg daily (high-intensity); target LDL <70 mg/dL | Active liver disease; pregnancy | LFTs at baseline; myalgias | URGENT | STAT | ROUTINE | - |
| Blood pressure management | - | Permissive hypertension acutely; goal <140/90 long-term | Target <180/110 first 24h; <140/90 after :: - :: :: Do NOT lower BP aggressively in first 24h unless >220/120 or end-organ damage | Symptomatic hypotension | BP q1h x24h, then q4h | STAT | STAT | ROUTINE | - |

### 3B. Symptomatic Treatments

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| IV fluids (isotonic saline) | IV | Maintain euvolemia; avoid hypotension | 75-125 mL/hr NS :: IV :: :: 75-125 mL/hr; adjust to maintain euvolemia; avoid D5W | Fluid overload, CHF | Fluid balance, I/Os | URGENT | ROUTINE | - | - |
| Pantoprazole | IV/PO | GI protection with DAPT | 40 mg IV daily; 40 mg PO daily :: IV/PO :: :: 40 mg daily | None | None | ROUTINE | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Cilostazol (triple antiplatelet) | PO | Asian populations; high-risk stenosis | 100 mg PO BID :: PO :: :: 100 mg BID; add to aspirin in select cases | Heart failure; bleeding | Bleeding, headache, palpitations | - | EXT | EXT | - |
| Prasugrel | PO | Clopidogrel resistance or failure | 60 mg PO x1 load; 10 mg PO daily :: PO :: :: 60 mg load then 10 mg daily; avoid if >75y or <60 kg | Prior TIA/stroke (black box); bleeding risk | Bleeding | - | EXT | EXT | - |

### 3D. Disease-Modifying or Chronic Therapies (Secondary Prevention)

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Aspirin (long-term) | PO | Lifelong secondary prevention | 81 mg PO daily :: PO :: :: 81 mg daily indefinitely | None | Active GI bleed | GI symptoms; annual CBC | - | ROUTINE | ROUTINE | - |
| Clopidogrel (monotherapy) | PO | Alternative to aspirin if aspirin-intolerant | 75 mg PO daily :: PO :: :: 75 mg daily | None | Active bleeding | Bleeding | - | ROUTINE | ROUTINE | - |
| Aspirin + extended-release dipyridamole (Aggrenox) | PO | Alternative antiplatelet regimen | 25/200 mg PO BID :: PO :: :: One capsule (25 mg ASA/200 mg ER dipyridamole) BID | None | Coronary stenosis (coronary steal); severe headache | Headache (often limits use); GI | - | ROUTINE | ROUTINE | - |
| Apixaban | PO | Atrial fibrillation-related TIA | 5 mg PO BID; 2.5 mg PO BID :: PO :: :: 5 mg BID (2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5) | Active major bleeding; mechanical valve | CrCl, bleeding signs | - | ROUTINE | ROUTINE | - |
| Rivaroxaban | PO | AF-related TIA | 20 mg PO daily; 15 mg PO daily :: PO :: :: 20 mg daily with food (15 mg if CrCl 15-50) | Active major bleeding; mechanical valve | CrCl, bleeding | - | ROUTINE | ROUTINE | - |
| Dabigatran | PO | AF-related TIA | 150 mg PO BID; 110 mg PO BID :: PO :: :: 150 mg BID (110 mg BID if CrCl 30-50 or age >80) | Active bleeding; CrCl <30; mechanical valve | CrCl, bleeding | - | ROUTINE | ROUTINE | - |
| Warfarin | PO | Mechanical valve; some hypercoagulable states | 2-10 mg PO daily adjusted :: PO :: :: Start 5 mg daily; adjust to INR 2-3 (2.5-3.5 for mechanical valve) | Baseline INR | Pregnancy; active bleeding; frequent falls | INR weekly then monthly | - | ROUTINE | ROUTINE | - |
| Lisinopril | PO | Blood pressure control for secondary prevention | 5 mg PO daily; 10 mg PO daily; 20 mg PO daily; 40 mg PO daily :: PO :: :: Start 5-10 mg daily; titrate to goal BP <130/80; max 40 mg | None | Angioedema; pregnancy; bilateral RAS; hyperkalemia | K+, Cr, BP | - | ROUTINE | ROUTINE | - |
| Amlodipine | PO | BP control; add-on therapy | 5 mg PO daily; 10 mg PO daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily | None | Severe aortic stenosis (relative) | Peripheral edema, BP | - | ROUTINE | ROUTINE | - |
| Chlorthalidone | PO | BP control; thiazide-like diuretic | 12.5 mg PO daily; 25 mg PO daily :: PO :: :: Start 12.5 mg daily; may increase to 25 mg daily | None | Severe hypokalemia; severe hyponatremia | K+, Na+, uric acid, glucose | - | ROUTINE | ROUTINE | - |
| Ezetimibe | PO | Add-on for LDL not at goal on statin | 10 mg PO daily :: PO :: :: 10 mg daily | None | Severe hepatic impairment | LFTs | - | ROUTINE | ROUTINE | - |
| PCSK9 inhibitor (evolocumab, alirocumab) | SC | LDL >70 despite maximal statin + ezetimibe | 140 mg SC q2wk; 420 mg SC monthly :: SC :: :: Evolocumab 140 mg q2wk or 420 mg monthly; alirocumab 75-150 mg q2wk | LFTs, lipid panel | None | Injection site reactions; LDL | - | - | ROUTINE | - |
| Icosapent ethyl (Vascepa) | PO | Triglycerides ≥150 despite statin; reduces CV events | 2 g PO BID :: PO :: :: 2 g BID with meals | None | Seafood/fish allergy (relative) | AF monitoring (slightly increased risk) | - | - | ROUTINE | - |
| Carotid endarterectomy (CEA) | Surgical | Symptomatic carotid stenosis 70-99%; 50-69% in select | Surgery :: Surgical :: :: Perform within 2 weeks of TIA if stable; high-volume surgeon | None | Unstable plaque with delay; total occlusion | Surgical complications; stroke | - | URGENT | - | - |
| Carotid artery stenting (CAS) | Endovascular | CEA high-risk; radiation neck; recurrent stenosis | Stenting :: Endovascular :: :: Alternative to CEA; requires DAPT | None | Tortuous anatomy; heavy calcification | Hyperperfusion syndrome; stroke | - | URGENT | - | - |
| PFO closure | Endovascular | Age <60, PFO with shunt, cryptogenic stroke/TIA | Device closure :: Endovascular :: :: Consider after comprehensive evaluation; DAPT post-procedure | None | Small PFO without shunt | AF (transient); device complications | - | - | EXT | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Neurology/Stroke consult for urgent evaluation, risk stratification, and secondary prevention optimization | STAT | STAT | ROUTINE | - |
| Cardiology consultation for atrial fibrillation management, anticoagulation decisions, and PFO evaluation | URGENT | URGENT | ROUTINE | - |
| Vascular surgery consultation for symptomatic carotid stenosis ≥50% to evaluate for endarterectomy timing | - | URGENT | ROUTINE | - |
| Interventional neurology for carotid stenting evaluation if CEA high-risk or anatomically unsuitable | - | URGENT | ROUTINE | - |
| Cardiac electrophysiology for recurrent AF management and potential ablation | - | - | ROUTINE | - |
| Registered dietitian for Mediterranean diet counseling and sodium restriction education | - | ROUTINE | ROUTINE | - |
| Smoking cessation counseling and pharmacotherapy initiation if current smoker | - | ROUTINE | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Call 911 immediately if symptoms return as this indicates high stroke risk (up to 10% in first 48 hours) | STAT | STAT | ROUTINE |
| Do not drive for at least 2-4 weeks after TIA per state regulations and stroke risk | URGENT | ROUTINE | ROUTINE |
| Take all medications as prescribed especially antiplatelet therapy which significantly reduces stroke risk | URGENT | ROUTINE | ROUTINE |
| Know stroke warning signs (FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911) | STAT | ROUTINE | ROUTINE |
| Keep follow-up appointments as early intervention reduces stroke risk by up to 80% | - | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Blood pressure target <130/80 mmHg to significantly reduce stroke recurrence risk | - | ROUTINE | ROUTINE |
| LDL target <70 mg/dL with high-intensity statin for secondary prevention | - | ROUTINE | ROUTINE |
| Smoking cessation (reduces stroke risk by 50% within 1 year of quitting) | - | ROUTINE | ROUTINE |
| Mediterranean diet emphasizing fruits, vegetables, whole grains, fish, and olive oil | - | ROUTINE | ROUTINE |
| Limit alcohol to ≤1 drink/day for women, ≤2 drinks/day for men | - | ROUTINE | ROUTINE |
| Regular aerobic exercise (150 min/week moderate or 75 min/week vigorous) | - | ROUTINE | ROUTINE |
| Weight management with target BMI 18.5-24.9 kg/m² | - | ROUTINE | ROUTINE |
| Sodium restriction <2300 mg/day (ideally <1500 mg if hypertensive) | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Migraine with aura | Gradual onset (minutes), visual scintillations, headache follows; younger patient | Clinical history; normal DWI |
| Seizure with Todd's paralysis | Preceding convulsion; confusion; gradual resolution over hours | EEG; clinical history |
| Hypoglycemia | Altered mentation, diaphoresis, tremor; resolves with glucose | Fingerstick glucose |
| Peripheral vertigo (BPPV, vestibular neuritis) | Isolated vertigo with nystagmus; positive Dix-Hallpike | HINTS exam; no central signs |
| Transient global amnesia | Isolated anterograde amnesia; repetitive questioning; resolves <24h | Clinical criteria; DWI may show hippocampal lesions |
| Functional neurological disorder | Inconsistent exam; incongruent symptoms; often with psychiatric comorbidity | Clinical exam; normal workup |
| Bell's palsy | Peripheral facial weakness (forehead involved); no other deficits | Clinical exam |
| Hypertensive encephalopathy | Severe HTN; headache; confusion; visual changes | BP, posterior MRI findings |
| Demyelinating disease (MS) | Younger patient; prior episodes; MRI with characteristic lesions | MRI brain/spine; CSF |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Neurological exam | q1h x 24h then q4h | Stable; no new deficits | Immediate imaging if worsening | STAT | STAT | - | - |
| Blood pressure | q1h x 24h then q4h | <180/110 acutely; <130/80 long-term | Titrate antihypertensives | STAT | STAT | ROUTINE | - |
| Cardiac rhythm (telemetry) | Continuous x 24-72h | Sinus rhythm | Anticoagulation if AF detected | URGENT | STAT | - | - |
| Extended cardiac monitoring | 14-30 days outpatient | Sinus rhythm | Anticoagulation if AF detected | - | - | ROUTINE | - |
| ABCD2 score | At presentation | Score <4 lower risk; ≥4 high risk | High-risk patients need admission or rapid TIA clinic | STAT | STAT | - | - |
| LDL cholesterol | Baseline, 6 weeks, then annually | <70 mg/dL | Intensify statin or add ezetimibe/PCSK9i | - | ROUTINE | ROUTINE | - |
| HbA1c | Baseline, then q3mo if diabetic | <7% | Optimize diabetes management | - | ROUTINE | ROUTINE | - |
| Creatinine/eGFR | With contrast; then annually | eGFR >30 | Dose-adjust medications | STAT | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Rapid TIA clinic (<24-48h) | ABCD2 <4; no acute findings on imaging; reliable patient with close follow-up |
| Admit to stroke unit | ABCD2 ≥4; DWI positive (minor stroke); symptomatic carotid stenosis; new AF; unable to complete workup as outpatient |
| Admit to ICU | Rare for isolated TIA; only if concurrent acute coronary syndrome or hemodynamic instability |
| Discharge with urgent follow-up | Completed rapid workup; started on secondary prevention; ABCD2 <4; no high-risk features |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Dual antiplatelet therapy (DAPT) for 21 days after minor stroke/TIA | Class I, Level A | [Wang et al. NEJM 2021 (CHANCE-2)](https://pubmed.ncbi.nlm.nih.gov/34265411/); [Johnston et al. NEJM 2018 (POINT)](https://pubmed.ncbi.nlm.nih.gov/29766749/) |
| High-intensity statin for LDL <70 mg/dL | Class I, Level A | [Amarenco et al. NEJM 2006 (SPARCL)](https://pubmed.ncbi.nlm.nih.gov/16899775/) |
| CEA for symptomatic carotid stenosis 70-99% | Class I, Level A | [NASCET Collaborators. NEJM 1991](https://pubmed.ncbi.nlm.nih.gov/1852179/) |
| ABCD2 score for TIA risk stratification | Class IIa, Level B | [Johnston et al. Lancet 2007](https://pubmed.ncbi.nlm.nih.gov/17258668/) |
| Extended cardiac monitoring for cryptogenic stroke | Class IIa, Level B | [Sanna et al. NEJM 2014 (CRYSTAL-AF)](https://pubmed.ncbi.nlm.nih.gov/24963567/) |
| PFO closure in cryptogenic stroke <60 years | Class IIa, Level B | [Mas et al. NEJM 2017 (CLOSE)](https://pubmed.ncbi.nlm.nih.gov/28902593/) |
| BP target <130/80 for secondary prevention | Class I, Level B | [AHA/ASA Guidelines 2021](https://pubmed.ncbi.nlm.nih.gov/34024117/) |
| Urgent TIA evaluation reduces stroke risk | Class I, Level B | [Rothwell et al. Lancet 2007 (EXPRESS)](https://pubmed.ncbi.nlm.nih.gov/17928046/) |
| DOACs preferred over warfarin for NVAF | Class I, Level A | [Ruff et al. Lancet 2014 (meta-analysis)](https://pubmed.ncbi.nlm.nih.gov/24315724/) |

---

## CHANGE LOG

**v1.0 (January 27, 2026)**
- Initial template creation
- ABCD2 risk stratification included
- DAPT protocols (POINT/CHANCE) incorporated
- Secondary prevention comprehensive coverage
